Commercial Space Company Risk / Opportunity Ranking

Thesis: Northwood Space has one of the cleaner opportunity setups in this screen because the reviewed sources membership rationale says it raised $100 million in a notable space startup funding deal, which can matter over a 1 year+ horizon by extending development and commercialization runway.

Why now: The rationale references article: and states Northwood Space raised $100 million in a notable spacetech funding deal; that size of financing is plausibly durable over a 1 year+ horizon, though recency cannot be fully validated from the absent article body.

Caveats: No representative article or provided in the visible evidence body. No direct evidence after recent evidence window are exposed despite the positive rationale. Funding alone does not prove technical or commercial execution.

Thesis: Orbital has a credible long-horizon opportunity signal because it was reported as having closed funding to verify a space-based data center concept, which supports continued development of an AI satellite constellation concept as of April 14, 2026.

Why now: The usable evidence is recent within the 90-day recent evidence window: an April 14, 2026 article said Orbital got funded by Andreessen Horowitz to verify its space-based data center concept, which is relevant to a 1 year+ horizon because financing can support technology proof and strategic positioning

Caveats: Evidence is supporting article context/weak context rather than direct positive events. No reviewed sources evidence of customers, revenue, launch schedule, or technical milestone completion. Same article appears in multiple weak-context rows and should not be treated as independent confirmation.

Thesis: Redwire has the strongest opportunity evidence in this screen because the reviewed sources includes dated within the recent evidence window article context for both a June 4, 2026 contract from Astrobiome Space to launch the inaugural mission in the world’s first commercial space greenhouse on the ISS and an April 8, 2026 article listing Redwire among the Andromeda awardees. Together, these point to activity across both commercial in-space applications and national-security space programs over a 1 year+ horizon.

Why now: The why-now case is the best in the set: a published June 4, 2026 article says Redwire was awarded a contract from Astrobiome Space for the inaugural flight of its commercial space greenhouse on the ISS. Earlier, on April 8, 2026, Defense Daily reported Redwire among companies awarded more than $1.8 billion total under the Andromeda SDA contracts. Those dated items suggest current business momentum that could matter over a 1 year+ horizon.

Caveats: Evidence is weak-context/supporting article context, not direct positive events. The standard-journal article carrying similar June 4, 2026 text is undated in the reviewed sources and should not be treated as independent confirmation. No material adverse evidence is available, but absence of negative evidence is not proof of low risk.

Thesis: Scout Space has credible growth-stage opportunity from a newly announced Series A financing and stated manufacturing expansion, which could support scaling of SDA sensors and software over a 1 year+ horizon.

Why now: A dated May 6, 2026 article says Scout raised up to $18 million Series A and will use the capital for mission execution and expansion of manufacturing capabilities, creating a current capacity-building milestone for the next year, May 6, 2026).

Caveats: Most available support is weak context/supporting article context rather than direct positive events. Blue Origin partnership articles are from 2025 and were outside the 90-day recent evidence window, so they should not drive recency-based ranking

Thesis: SES has the strongest current opportunity setup in this screen because within the recent evidence window dated evidence says SES was selected as a prime contractor in the U.S. Space Force Protected Tactical Satcom-Global program, with a combined $437.7 million award for SES and Viasat to each build and operate a satellite. That indicates current government program relevance with potential multiyear strategic value.

Why now: The key evidence is recent and within the recent evidence window: a June 11, 2026 SpaceNews article says SES was selected last month as a prime contractor under the PTS-G program, with K2 Space providing SES's satellite platform

Caveats: Reviewed evidence is still supporting article context rather than a direct company filing. The Impulse transportation agreement is older and outside the 90-day recent evidence window.

Thesis: Starcloud is the strongest opportunity candidate in this screen because recent dated article context indicates capital raised and incremental network buildout steps for its orbital data center concept. A March 30, 2026 article says Starcloud raised $170 million at a $1.1 billion valuation. A later May 26, 2026 article says Starcloud announced a contract for more than 50 Starlink Mini Lasers to equip at least 25 satellites and use Starlink as a global data-relay network. A June 10, 2026 article further describes Starcloud as having raised about $200 million to date for a proposed constellation of 88,000 orbital data centers.

Why now: Within the 90-day recent evidence window, Starcloud has the clearest sequence of dated business-state updates: funding on March 30, 2026, network-equipment contract on May 26, 2026, and additional context on capital raised and market positioning on June 10, 2026, For a 1 year+ horizon, that sequence supports an active buildout story even though evidence quality is not fully direct.

Caveats: All usable evidence is supporting article context; the reviewed sources provide no direct positive or negative dated event/facts. Repeated Starcloud claims across articles are not independent confirmation under the evidence standard. Opportunity and risk both remain dependent on future execution over a long horizon.

Thesis: Synspective has the strongest opportunity evidence in this screen because multiple within the recent evidence window dated article-context items point to operational and strategic scaling: a May 1, 2026 article says Rocket Lab launched Synspective's ninth StriX SAR satellite, improving its ability to deliver persistent Earth observation capabilities; a June 3, 2026 press release says Synspective and KSAT expanded their strategic alliance to support constellation expansion; and a May 21, 2026 company page describes an operating fleet, SAR data sales, and solution services for government and commercial customers

Why now: The recency stack is favorable for a 1 year+ thesis: May 1, 2026 launch progress, May 21, 2026 operating-profile context, and June 3, 2026 alliance expansion together suggest that constellation buildout and service-capability scaling were active in the most recent recent evidence window period

Caveats: Evidence is supporting article context and mostly neutral-polarity in reviewed sources structure, not direct dated event/facts. Two key supportive items are company-sourced pages/press releases. No retained adverse evidence exists, but absence of bad news is not proof of low risk.

Thesis: Recent article context says UNASTELLA raised $24 million to develop its own launch vehicles and engines, a meaningful capital-and-capability milestone for a rocket startup with potential multi-year product development relevance.

Why now: The funding context is dated June 1, 2026 and sits well within the 90-day recent evidence window, making it recent enough to support a 1 year+ development runway thesis. Source date: June 1, 2026

Caveats: Evidence is from a LinkedIn space briefing and is supporting article context only. No direct product milestone, customer, or contract evidence is available.

Thesis: Vast Space has the strongest opportunity profile in this screen because within the recent evidence window dated article context indicates a strategic expansion from commercial space stations into satellite manufacturing through a new high-power satellite bus line, with one article saying the new line targets communications, Earth observation, national security, and orbital data center constellations, and another saying Vast already has a customer. This product-line expansion can matter over a 1 year+ horizon if it broadens revenue sources beyond stations, May 19, 2026, May 19, 2026).

Why now: The timing case is stronger than peers because the product expansion articles are dated May 19, 2026 and May 20, 2026, within the 90-day recent evidence window, and represent a potentially durable strategic change: moving into satellite buses rather than remaining only a station developer, May 19, 2026, May 20, 2026).

Caveats: Retained evidence is weak context supporting article context; there are no direct positive event/facts available. The March 2026 financing articles are outside the 90-day recent evidence window and cannot be primary support, even though they appear in representative articles. Several retained rows summarize the same basic product announcement and should not be treated as independent confirmation.

Thesis: Voyager Space has the strongest reviewed sources-supported opportunity because within the recent evidence window it has dated evidence of a $16.5 million DARPA Phase 2 contract and dated company context showing electric propulsion capabilities for satellite constellations and broader space technologies, supporting a durable defense-space revenue and capability narrative over a 1 year+ horizon

Why now: The timing is comparatively favorable: Voyager has dated within the recent evidence window evidence published May 26, 2026 for a $16.5M DARPA Phase 2 contract, May 29, 2026 defense/national security capability context, and June 4, 2026 current company capability context, all within the reviewed sources recent evidence window and relevant to a 1 year+ horizon

Caveats: Much of the evidence is supporting article context rather than direct positive rows. Some cited capability pages are company-provided materials. Ticker is absent in the required company entry even though external articles reference NYSE: VOYG; this output preserves the required ticker field from the input.

Thesis: Recent large Series B financing to build an AI-powered Earth mapping constellation supports a medium-strength long-horizon scaling opportunity.

Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize.

Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available.

Thesis: Aalyria Technologies appears attractive on reviewed sources evidence because it is directly included among awardees in U.S. Space Force Golden Dome contracts, a durable government-program signal that can matter over a 1 year+ horizon.

Why now: Current relevance is tied to the cited Space Force Golden Dome contract award context in article, though the reviewed sources omits the and representative article details.

Caveats: No article is supplied for the cited support article. Opportunity rests on a single contract-related rationale summary. Contract inclusion alone does not reveal contract size, economics, or conversion pace.

Thesis: Aavuus has the strongest recent opportunity setup in this screen because a dated article says it raised pre-seed funding and is building a global laser-based tracking network for debris tracking and collision avoidance in LEO, indicating financing plus product/infrastructure development in orbital safety and space domain awareness.

Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026

Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation.

Thesis: The reviewed sources states Astroscale focuses on satellite repair, refueling, and debris removal, and partnered with SKY Perfect JSAT for on-orbit satellite services. That indicates strategic positioning in an emerging service layer with potentially durable 1 year+ relevance.

Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible.

Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated.

Thesis: Among the covered names, CesiumAstro has the clearest positive business context: an external article summary states it raised a $270M Series C round, bringing total funding to $655M, and provides communication systems for satellites, UAVs, launch vehicles, and other space or airborne platforms, suggesting better capitalization and broad platform relevance if that financing remains available to drive growth

Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking

Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source.

Thesis: Constellr has the best supported long-horizon opportunity in this screen. A dated article published April 16, 2026 says constellr operates a proprietary satellite constellation for thermal intelligence, launched its first satellite in January 2025, and closed a €37 million Series A in February 2026, which together indicate product deployment plus fresh capital to scale over a 1 year+ horizon.

Why now: Why now is relatively strongest here because the retained evidence is within the 90-day recent evidence window and dated April 16, 2026, summarizing recent business-state milestones including a first satellite launch in January 2025 and a Series A closed in February 2026.

Caveats: Evidence is external article context, not a direct company filing or contract announcement.

Thesis: Eycore has a modest opportunity signal because a dated May 2026 article says it launched Eycore-1, its first Earth observation satellite equipped with the company's SAR technology. A first in-orbit asset can be strategically important over a 1 year+ horizon if it enables product validation and future commercial traction.

Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage.

Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided.

Thesis: Reviewed evidence rationale says Guodian Gaoke received the first trial license for satellite IoT services and that Tianqi low-orbit IoT constellation Phase I is complete. A completed initial constellation phase plus first-trial-license status is one of the better long-horizon setup signals in this otherwise thin-evidence batch.

Why now: The why-now would be the reported trial license and completed Phase I constellation, but the reviewed sources does not provide the underlying article summary or date-specific evidence for stronger timing confidence.

Caveats: Phase2 membership rationale references: but no summary/evidence row is available to cite directly. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Score exceeds Beijing Guodian High-Tech slightly because rationale mentions both licensing and constellation completion.

Thesis: The reviewed sources membership rationale states Interlune won a $6.9M NASA contract for lunar resource development with a payload for lunar regolith volatiles and extraction demonstrations. For a 1 year+ horizon, that is a concrete external validation event that could support technology maturation and future lunar-resource positioning.

Why now: The key 'why now' is the cited NASA contract in article: but the reviewed sources does not include the article summary or, so exact date and latest status are not visible here.

Caveats: Opportunity case relies on membership rationale rather than included direct article evidence. A $6.9M contract is positive validation, but contract size alone may not be enough to de-risk a lunar-resource business. No negative evidence is provided, so risk mostly reflects execution uncertainty.

Thesis: Iridium has a moderate long-horizon opportunity case from current evidence that it operates a 66-satellite LEO constellation providing global mobile satellite communications, a durable strategic asset position if demand remains resilient.

Why now: The current support is an April 3, 2026 article-level overview of Iridium’s constellation and service footprint rather than a new event, so timing fit is only medium.

Caveats: Evidence is supporting article context, not a fresh contract or earnings-linked milestone.

Thesis: Risk is mainly early-stage execution uncertainty and limited evidence depth: only two articles considered and zero available evidence after recent evidence window.

Why now: Why now is weak because the reviewed sources does not establish current demo timing or funding status with direct evidence after recent evidence window.

Caveats: Private company with thin visible evidence in these reviewed sources. Mission/demo status cannot be validated from available evidence.

Thesis: The main risk is evidentiary: the reviewed sources lack strong recent company-specific event/facts within the recent evidence window, limiting confidence on current execution state.

Why now: Why-now is weak because retained evidence after recent evidence window is mostly undated context; one cited article is from February 14, 2026 and therefore outside the 90-day evidence window, while the remaining available context is undated.

Caveats: Reviewed evidence membership rationale mentions a €119 million ESA contract, but no citeable retained row for that contract is included here. Series D funding mention is in a February 14, 2026 article outside the 90-day recent evidence window. Undated context is not recency proof.

Thesis: The risk is that none of the cited grant or partnership evidence is actually available into the kept post-recent evidence window evidence set, so durability, funding size, execution status, and commercial conversion remain unverified in the reviewed sources.

Why now: The reviewed sources references: and: in the membership rationale, suggesting relatively recent strategic developments, but the coverage report still shows zero evidence after recent evidence window, so timing confidence is limited.

Caveats: Positive thesis relies on membership rationale, not available direct evidence. Partnership evidence cannot be expanded through relation propagation beyond what is explicitly stated.

Thesis: Main risk in these reviewed sources is evidence absence rather than a documented business setback. With no available within the recent evidence window direct positive or negative evidence, visibility into current traction, financing, or execution is poor.

Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, making recency and business-state assessment uncertain.

Caveats: Phase-2 membership rationale references: but no or available evidence row is provided in these reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Cannot treat cohort membership as thesis attractiveness.

Thesis: Risk is mostly normal scale-up and execution risk from pursuing ambitious transportation and recovery-platform goals; the reviewed sources does not provide direct negative evidence such as delays, litigation, or financing stress.

Why now: The catalyst is recent and dated: the financing article is timestamped June 19, 2026, which is inside the 90-day recent evidence window and recent enough to matter for a 1 year+ business-building horizon.

Caveats: Support is still supporting article context rather than direct positive events. Only one article is available, limiting corroboration.

Thesis: The reviewed sources does not provide material negative evidence, but development and mission-execution risk remain implicit because the thesis rests on a demonstration mission rather than proven commercial scale.

Why now: The membership rationale specifically points to the LOXSAT mission demonstration as the current relevance driver, citing article: but the reviewed sources does not include the article or more detailed dated evidence fields.

Caveats: Underlying article is not provided in the reviewed sources. Score is based on membership rationale summary rather than available direct evidence. Single-mission validation is weaker than broad commercial traction.

Thesis: The evidence is minimal and mostly acquisition context rather than direct company-specific operating evidence. Without retained post-recent evidence window detail, there is no basis for a stronger opportunity or risk call, and ownership/status changes may have already altered standalone operating exposure.

Why now: No retained evidence establishes current milestone timing or post-acquisition integration progress, so there is no strong why-now supported in these reviewed sources.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Acquisition context is weaker than direct operating evidence.

Thesis: The main risk is evidentiary uncertainty: there is no available direct adverse evidence, but there is also no post-recent evidence window operating, financing, customer, or execution evidence to confirm momentum.

Why now: There is no credible 'why now' catalyst in the reviewed sources because articles after recent evidence window and evidence after recent evidence window are both zero for this company. The only cited support is older or excluded from the active evidence set: article, referenced in the membership rationale, was outside the kept recent evidence window according to the company coverage report.

Caveats: No evidence were available after recent evidence filtering. No representative articles or additional_company_articles were provided. Membership rationale is weaker than direct event/fact evidence.

Thesis: The evidence is limited to one recent article-level source and does not provide strong company-specific downside evidence, so risk stays low but uncertainty remains high.

Why now: A dated May 26, 2026 article puts a fresh NASA program win into the current evidence window, which can matter over a 1 year+ horizon even if revenue realization is later.

Caveats: Only one within the recent evidence window article is available. Evidence is supporting article context rather than stronger extracted direct events. Timing of mission realization is long-dated relative to the evidence window.

Thesis: Risk is mainly lack of current evidentiary confirmation rather than documented business trouble.

Why now: There is no within the recent evidence window evidence available in these reviewed sources for GalaxEye Space; timing and maturity of current milestones cannot be confirmed from reviewed sources evidence.

Caveats: Membership rationale cites article IDs and, but their article content is not provided here for citation. Evidence recent evidence review shows 0 kept rows. This entity may overlap with GalaxEye Space Solutions Private Ltd, but the output contract requires scoring both separately.

Thesis: Risk is mainly evidence uncertainty rather than documented adverse developments, because no direct negative evidence or current operating milestones were available after the recent evidence filter.

Why now: There is no within the recent evidence window evidence available for this entity in the reviewed sources; recency of any business progress is uncertain.

Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff for this entity. Membership rationale references article IDs, and: but no article summaries or direct evidence are included in these reviewed sources for citation-level use. Scores are constrained by absence of directional evidence, not by a proven negative business outcome.

Thesis: No material adverse evidence is present, but the evidence is too limited and research-oriented to reduce uncertainty materially.

Why now: The reviewed sources references article: for the research institute setup, yet does not provide the article or direct event details to assess timing or commercial conversion.

Caveats: Only one article is considered and no representative article object is provided. Research institute formation is weaker than product, contract, or financing milestones. Commercial impact timing is unclear.

Thesis: The same evidence creates moderate execution/classification risk: the company may have financing momentum, but the reviewed sources does not establish that it fits the target cohort or that the funding translates into durable business opportunity. No direct adverse event is available.

Why now: The only possible timing angle is the referenced seed raise in the membership rationale, but no -backed available evidence remains after the recent evidence filter, so recency and impact cannot be validated for scoring.

Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Funding context does not prove target-cohort fit.

Thesis: Risk is modest because the evidence base is only one undated, supporting article context with no direct company events beyond funding context, making current status and durability uncertain

Why now: For a 1 year+ horizon, funding can matter, but recency is uncertain because the article is explicitly undated and the reviewed sources say undated external evidence is relevance context rather than recency proof

Caveats: The evidence is weak context and supporting article context, not direct structured company event/fact evidence. The article is undated; the reviewed sources explicitly says recency-sensitive claims should be treated cautiously. Same-article repeated rows are not independent confirmation.

Thesis: The main risk is evidentiary rather than operational: the reviewed sources contain no direct negative evidence, but also no company-specific contract value, backlog, execution milestone, or follow-on detail. The Andromeda item is supporting article context and same-article repeats are not independent confirmation, so the opportunity could be overstated if General Atomics' role is small or non-recurring., April 8, 2026

Why now: The catalyst is recent within the reviewed sources recent evidence window: the is April 8, 2026, and it describes Space Force awarding Andromeda contracts, a potentially durable procurement cycle relevant to a 1 year+ horizon., April 8, 2026

Caveats: This is supporting article context/weak context, not a direct company event row. Same-article repeated rows in the reviewed sources are not independent confirmation.

Thesis: The main risk is lack of current standalone visibility: because evidence appears tied to acquired-business context and no retained rows are included, current operating status, ownership implications, and commercial significance cannot be established from these reviewed sources.

Why now: There is no retained within the recent evidence window evidence. Any thesis would rely on older context referenced in the membership rationale, which is insufficient for a stronger rank.

Caveats: Reviewed evidence references acquired-business context rather than current standalone operations. No representative articles or retained evidence are included. Low scores reflect missing timely evidence, not a directional call on the business.

Thesis: Risk appears limited based on the reviewed sources only because there is no adverse evidence, but confidence is low since there is also no direct traction, contract, funding, or milestone evidence available.

Why now: The reviewed sources offers no recent evidence window-supported event timing for a why-now view.

Caveats: The membership rationale says GHGSat is the world's leading commercial greenhouse gas monitoring satellite company, but the supporting article content is not available here for ranking use. Absence of negative evidence is not positive evidence.

Thesis: There is no direct adverse evidence in the reviewed sources; risk is limited to uncertainty from missing current evidence rather than any documented deterioration.

Why now: No within the recent evidence window evidence were available for Globalstar in these reviewed sources, so there is no current catalyst basis to elevate either opportunity or risk.

Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. Membership rationale cites article IDs, and: but those article contents are not provided here for direct factual citation. Public company status does not improve ranking without directional evidence.

Thesis: No direct negative evidence is shown; key risk is uncertainty around monetization, expansion beyond Phase I, and lack of corroborating direct evidence in the reviewed sources.

Why now: The why-now would be the reported trial license and completed Phase I constellation, but the reviewed sources does not provide the underlying article summary or date-specific evidence for stronger timing confidence.

Caveats: Phase2 membership rationale references: but no summary/evidence row is available to cite directly. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Score exceeds Beijing Guodian High-Tech slightly because rationale mentions both licensing and constellation completion.

Thesis: The reviewed sources also says the company-specific operating category is not clearly established from the provided evidence alone. That uncertainty, plus the lack of retained direct evidence, limits confidence in any positive thesis.

Why now: Space-based AI computing could be strategically relevant over 1 year+, but the reviewed sources provide no retained dated evidence to confirm partnership scope, timing, or commercial milestones.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Partnership mention alone is insufficient to prove durable company impact.